1
Guo L#, Zhang Q, Zhang C, Huang T, Ren L, Cao B*, Wang J*. Assessment of Antibody and T-Cell Responses to the SARS-CoV-2 Virus and Omicron Variant in Unvaccinated Individuals Recovered From COVID-19 Infection in Wuhan, China. JAMA Netw Open. 2022 Apr 1;5(4):e229199. doi: 10.1001/jamanetworkopen.2022.9199.
2
Zhao J#, Li Z#, Zhang Y, Liu X, Lu B*, Cao B*. Convergence of MCR-8.2 and Chromosome-Mediated Resistance to Colistin and Tigecycline in an NDM-5-Producing ST656 Klebsiella pneumoniae Isolate From a Lung Transplant Patient in China. Front Cell Infect Microbiol. 2022 Jul 11;12:922031. doi: 10.3389/fcimb.2022.922031. eCollection 2022.
3
Shang L#, Cao B*. Protein-based vaccine as the booster dose for adults: evidence and beyond. Lancet Infect Dis. 2022 Aug 10. pii: S1473-3099(22)00447-9. doi: 10.1016/S1473-3099(22)00447-9.
4
Yang X#, Hou C, Shen Y, Zhang M, Zhang K, Wang F, Liu Y, Ma X, Cheng L, Kang J, Hu B, Wang M, Zeng L, Wang Y, He Y, Cao G, Jiang J, Jones P, Cao B*, Li L*. Two-Year Health Outcomes in Hospitalized COVID-19 Survivors in China. JAMA Netw Open. 2022 Sep 1;5(9):e2231790. doi: 10.1001/jamanetworkopen.2022.31790.
5
Zhang H#, Cao B*. Post-infection rehabilitation of COVID-19 patients: Findings and prospects. Lancet Reg Health Eur. 2022 Nov;22:100496. doi: 10.1016/j.lanepe.2022.100496. Epub 2022 Sep 1.
6
Wang Z#, Deng T#, Zhang Y#, Niu W, Nie Q, Yang S, Liu P, Pei P, Chen L, Li H*, Cao B*. ACE2 can act as the secondary receptor in the FcgammaR-dependent ADE of SARS-CoV-2 infection. iScience. 2022 Jan 21;25(1):103720. doi: 10.1016/j.isci.2021.103720. Epub 2021 Dec 31.
7
Cui D#, Chen S#, Feng L#, Jia M#, Wang Y#, Xiao W, Sun Y, Huang Q, Ma L, Leng Z, Wang H, Cao B*, Yang W*, Yang J*, Wang C*.Long-term outcomes in COVID-19 patients who recovered from the first wave of the pandemic.Natl Sci Rev. 2022 Sep 20;9(11):nwac192. doi: 10.1093/nsr/nwac192. eCollection 2022 Nov.
8
Zou X#, Nguyen M, Overbeek J, Cao B*, Davis JJ*.Classification of bacterial plasmid and chromosome derived sequences using machine learning.PLoS One. 2022 Dec 16;17(12):e0279280. doi: 10.1371/journal.pone.0279280. eCollection 2022.
9
Zhang H#, Li X#, Huang L#, Gu X#, Wang Y, Liu M, Liu Z, Zhang X, Yu Z, Wang Y*, Huang C*, Cao B*.Lung-function trajectories in COVID-19 survivors after discharge: A two-year longitudinal cohort study.EClinicalMedicine. 2022 Sep 28;54:101668. doi: 10.1016/j.eclinm.2022.101668. eCollection 2022 Dec.
10
Cui D#, Wang Y#, Huang L#, Gu X#, Huang Z, Mu S, Wang C*, Cao B*. Rheumatic Symptoms Following Coronavirus Disease 2019 (COVID-19): A Chronic Post-COVID-19 Condition. Open Forum Infect Dis. 2022 May 23;9(6):ofac170. doi: 10.1093/ofid/ofac170.
11
Han X#, Chen L, Li H, Zhou F, Xing X, Zhang C, Suo L, Wang J, Liu X*, Cao B*, CAP-China network. Prognostic Factors for Cardiovascular Events in Elderly Patients with Community Acquired Pneumonia: Results from the CAP-China Network. Clin Interv Aging. 2022 Apr 23;17:603-614. doi: 10.2147/CIA.S356925.
12
Zhuo X#, Zhao J, Wang L, Sun B, Sun L, Wang C, Li B, Fan Y, Liu Y*, Cao B*. Development and evaluation of a multiplex quantitative polymerase chain reaction assay for detecting bacteria associated with lower respiratory tract infection. Int J Infect Dis. 2022 May 26;122:202-211. doi: 10.1016/j.ijid.2022.05.052.
13
Li H#, Zhao M#, Zhang H, Quan C, Zhang D, Liu Y, Liu M, Xue C, Tan S, Guo Y, Zhao Y, Wu G, Gao GF*, Cao B*, Liu WJ*. Pneumonia Severity and Phase Linked to Virus-Specific T Cell Responses with Distinct Immune Checkpoints during pH1N1 Infection.J Immunol. 2022 May 1;208(9):2154-2162. doi: 10.4049/jimmunol.2101021.
14
Xu J#, Cao B*. Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19. Eur Respir J. 2022 Jan 6;59(1):2102002. doi: 10.1183/13993003.02002-2021.
15
Gu X#, Cao B*. Understanding of COVID-19 from infection-fatality ratio. Lancet. 2022 Apr 16;399(10334):1442-1443. doi: 10.1016/S0140-6736(22)00281-1.
16
Zhang Y#, Zhao J, Han J, Fan Y, Xiong Z, Zou X, Li B, Liu X, Li Z, Lu B*, Cao B*. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa. Microbiol Spectr. 2022 Apr 27;10(2):e0274021. doi: 10.1128/spectrum.02740-21.
